Antibody data
- Antibody Data
- Antigen structure
- References [71]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [3]
- Flow cytometry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13912 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ERCC1 Monoclonal Antibody (8F1)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13912 targets ERCC1 in IP, IHC (P), FACS and WB applications and shows reactivity with human, mouse and rat samples.
- Antibody clone number
- 8F1
- Concentration
- 0.2 mg/mL
Submitted references Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold.
Factors affecting platinum sensitivity in cervical cancer.
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.
Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Clinicopathological significance of ERCC1 expression in breast cancer.
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients.
Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.
Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer.
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Mutations of the SLX4 gene in Fanconi anemia.
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells.
Molecular characterization of spontaneous mesenchymal stem cell transformation.
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Influence of oxygen on the radiosensitivity of human glioma cell lines.
Kulkarni S, Solomon M, Pankaj D, Carnelio S, Chandrashekar C, Shetty N
Journal of oral and maxillofacial pathology : JOMFP 2020 Jan-Apr;24(1):20-25
Journal of oral and maxillofacial pathology : JOMFP 2020 Jan-Apr;24(1):20-25
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A, Langdon SP, Um I, Kay C, Francis KE, Harrison DJ, Smith VA
BMC cancer 2016 Mar 10;16:205
BMC cancer 2016 Mar 10;16:205
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Cubillo A, Rodriguez-Pascual J, López-Ríos F, Plaza C, García E, Álvarez R, de Vicente E, Quijano Y, Hernando O, Rubio C, Perea S, Sanchez G, Hidalgo M
American journal of clinical oncology 2016 Jun;39(3):236-42
American journal of clinical oncology 2016 Jun;39(3):236-42
UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold.
Tian Y, Paramasivam M, Ghosal G, Chen D, Shen X, Huang Y, Akhter S, Legerski R, Chen J, Seidman MM, Qin J, Li L
Cell reports 2015 Mar 31;10(12):1957-66
Cell reports 2015 Mar 31;10(12):1957-66
Factors affecting platinum sensitivity in cervical cancer.
Kato R, Hasegawa K, Torii Y, Udagawa Y, Fukasawa I
Oncology letters 2015 Dec;10(6):3591-3598
Oncology letters 2015 Dec;10(6):3591-3598
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, Szczylik C, Jakobsen A
International journal of oncology 2014 May;44(5):1736-44
International journal of oncology 2014 May;44(5):1736-44
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
Muley TR, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, Schneider MA, Schnabel PA, Warth A
Anticancer research 2014 Jul;34(7):3707-13
Anticancer research 2014 Jul;34(7):3707-13
ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.
Kalogeraki A, Karvela-Kalogeraki I, Tamiolakis D, Petraki P, Saridaki Z, Tzardi M
Revista portuguesa de pneumologia 2014 Jul-Aug;20(4):200-7
Revista portuguesa de pneumologia 2014 Jul-Aug;20(4):200-7
Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.
Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY, Lee SH
Cancer research and treatment 2014 Jan;46(1):55-64
Cancer research and treatment 2014 Jan;46(1):55-64
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A, Hernando-Requejo O, García-García E, Rodriguez-Pascual J, De Vicente E, Morelli P, Rubio C, López-Ríos F, Muro A, López U, Prados S, Quijano Y, Hidalgo M
American journal of clinical oncology 2014 Apr;37(2):117-21
American journal of clinical oncology 2014 Apr;37(2):117-21
Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M, Hoshino T
PloS one 2013;8(8):e71356
PloS one 2013;8(8):e71356
Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D
Lung cancer (Amsterdam, Netherlands) 2013 Nov;82(2):324-9
Lung cancer (Amsterdam, Netherlands) 2013 Nov;82(2):324-9
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N
Clinical lung cancer 2013 Mar;14(2):164-71
Clinical lung cancer 2013 Mar;14(2):164-71
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC
The New England journal of medicine 2013 Mar 21;368(12):1101-10
The New England journal of medicine 2013 Mar 21;368(12):1101-10
Clinicopathological significance of ERCC1 expression in breast cancer.
Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A, Schmitt F
Pathology, research and practice 2013 Jun;209(6):331-6
Pathology, research and practice 2013 Jun;209(6):331-6
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D, Wei P, An G, Chen W
Journal of cardiothoracic surgery 2013 Jun 10;8:149
Journal of cardiothoracic surgery 2013 Jun 10;8:149
Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Mendoza J, Martínez J, Hernández C, Pérez-Montiel D, Castro C, Fabián-Morales E, Santibáñez M, González-Barrios R, Díaz-Chávez J, Andonegui MA, Reynoso N, Oñate LF, Jiménez MA, Núñez M, Dyer R, Herrera LA
British journal of cancer 2013 Jul 9;109(1):68-75
British journal of cancer 2013 Jul 9;109(1):68-75
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Dec 1;19(23):6633-43
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Dec 1;19(23):6633-43
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A, Bio-FAST trial group
British journal of cancer 2013 Apr 30;108(8):1695-703
British journal of cancer 2013 Apr 30;108(8):1695-703
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrois L, Finetti P, Giraud P, Racadot S, Morinière S, Sudaka A, Van Obberghen-Schilling E, Milano G
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Sep 15;18(18):5123-33
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Sep 15;18(18):5123-33
Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L
Oral oncology 2012 Oct;48(10):964-968
Oral oncology 2012 Oct;48(10):964-968
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients.
Planchard D, Camara-Clayette V, Dorvault N, Soria JC, Fouret P
Cancer 2012 Oct 15;118(20):5015-25
Cancer 2012 Oct 15;118(20):5015-25
Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.
Monica V, Longo M, Felice B, Scagliotti GV, Papotti M, Novello S
Clinical lung cancer 2012 Nov;13(6):416-23
Clinical lung cancer 2012 Nov;13(6):416-23
Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, Shin B, Lees-Miller SP, Magliocco AM
Head & neck 2012 Jun;34(6):785-91
Head & neck 2012 Jun;34(6):785-91
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Jan;7(1):249-56
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Jan;7(1):249-56
Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer.
Facista A, Nguyen H, Lewis C, Prasad AR, Ramsey L, Zaitlin B, Nfonsam V, Krouse RS, Bernstein H, Payne CM, Stern S, Oatman N, Banerjee B, Bernstein C
Genome integrity 2012 Apr 11;3(1):3
Genome integrity 2012 Apr 11;3(1):3
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-Rayes BF, Kauh JS, Sarmiento J, Staley CA 3rd, Volkan Adsay N
Annals of surgical oncology 2011 Sep;18(9):2699-705
Annals of surgical oncology 2011 Sep;18(9):2699-705
The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Nov;21(8):1479-85
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Nov;21(8):1479-85
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 May;6(5):927-33
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 May;6(5):927-33
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Rodrigo RS, Nathalie A, Elodie T, Gonzalo GA, Philippe T, Françoise D, Julien D, Angela C, Bérénice B, Jean-Yves B, Jean-Michel C, Jean B, Sylvie B, Axel le C
European journal of cancer (Oxford, England : 1990) 2011 Jun;47(9):1319-27
European journal of cancer (Oxford, England : 1990) 2011 Jun;47(9):1319-27
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, Sheen SS, Lim HY
Digestive diseases and sciences 2011 Jan;56(1):131-8
Digestive diseases and sciences 2011 Jan;56(1):131-8
Mutations of the SLX4 gene in Fanconi anemia.
Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A
Nature genetics 2011 Feb;43(2):142-6
Nature genetics 2011 Feb;43(2):142-6
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.
Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, Oostra AB, Eirich K, Korthof ET, Nieuwint AW, Jaspers NG, Bettecken T, Joenje H, Schindler D, Rouse J, de Winter JP
Nature genetics 2011 Feb;43(2):138-41
Nature genetics 2011 Feb;43(2):138-41
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2011 Feb;16(1):74-82
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2011 Feb;16(1):74-82
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Vilmar AC, Santoni-Rugiu E, Sørensen JB
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Sep;21(9):1817-1824
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Sep;21(9):1817-1824
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E
Endocrine-related cancer 2010 Sep;17(3):797-807
Endocrine-related cancer 2010 Sep;17(3):797-807
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
British journal of cancer 2010 Sep 7;103(6):845-51
British journal of cancer 2010 Sep 7;103(6):845-51
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN
Anticancer research 2010 Oct;30(10):4289-95
Anticancer research 2010 Oct;30(10):4289-95
Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.
Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010 Nov;97(2):352-9
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010 Nov;97(2):352-9
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A
Gynecologic oncology 2010 Nov;119(2):325-31
Gynecologic oncology 2010 Nov;119(2):325-31
Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS
Lung cancer (Amsterdam, Netherlands) 2010 May;68(2):288-94
Lung cancer (Amsterdam, Netherlands) 2010 May;68(2):288-94
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou Ch, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilas G
Cancer chemotherapy and pharmacology 2010 May;65(6):1009-21
Cancer chemotherapy and pharmacology 2010 May;65(6):1009-21
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Mar 20;28(9):1534-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Mar 20;28(9):1534-9
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Vilmar A, Santoni-Rugiu E, Sørensen JB
European journal of cancer (Oxford, England : 1990) 2010 Jun;46(9):1554-62
European journal of cancer (Oxford, England : 1990) 2010 Jun;46(9):1554-62
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Wang X, Zhao J, Yang L, Mao L, An T, Bai H, Wang S, Liu X, Feng G, Wang J
Medical oncology (Northwood, London, England) 2010 Jun;27(2):484-90
Medical oncology (Northwood, London, England) 2010 Jun;27(2):484-90
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Apr;5(4):453-9
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Apr;5(4):453-9
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL
Japanese journal of clinical oncology 2010 Apr;40(4):286-93
Japanese journal of clinical oncology 2010 Apr;40(4):286-93
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.
Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D
Journal of oncology 2009;2009:305908
Journal of oncology 2009;2009:305908
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS
Lung cancer (Amsterdam, Netherlands) 2009 Sep;65(3):377-82
Lung cancer (Amsterdam, Netherlands) 2009 Sep;65(3):377-82
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M
Endocrine-related cancer 2009 Sep;16(3):907-18
Endocrine-related cancer 2009 Sep;16(3):907-18
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Holm B, Mellemgaard A, Skov T, Skov BG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Sep 10;27(26):4254-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Sep 10;27(26):4254-9
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Oct;4(10):1212-20
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Oct;4(10):1212-20
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A
Lung cancer (Amsterdam, Netherlands) 2009 Jul;65(1):105-11
Lung cancer (Amsterdam, Netherlands) 2009 Jul;65(1):105-11
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.
Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P
Annals of oncology : official journal of the European Society for Medical Oncology 2009 Jul;20(7):1257-63
Annals of oncology : official journal of the European Society for Medical Oncology 2009 Jul;20(7):1257-63
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD, Waldstrøm M, Jakobsen A
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009 Jul;19(5):820-5
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009 Jul;19(5):820-5
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY
British journal of cancer 2009 Jan 27;100(2):298-304
British journal of cancer 2009 Jan 27;100(2):298-304
Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
Wu Y, Mitchell TR, Zhu XD
Mechanisms of ageing and development 2008 Oct;129(10):602-10
Mechanisms of ageing and development 2008 Oct;129(10):602-10
ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
Sidoni A, Cartaginese F, Colozza M, Gori S, Crinó L
Breast cancer research and treatment 2008 Oct;111(3):569-70
Breast cancer research and treatment 2008 Oct;111(3):569-70
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H
Lung cancer (Amsterdam, Netherlands) 2008 Mar;59(3):377-84
Lung cancer (Amsterdam, Netherlands) 2008 Mar;59(3):377-84
Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jul 1;14(13):4225-31
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jul 1;14(13):4225-31
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY
Lung cancer (Amsterdam, Netherlands) 2008 Jan;59(1):95-104
Lung cancer (Amsterdam, Netherlands) 2008 Jan;59(1):95-104
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB
European journal of cancer (Oxford, England : 1990) 2008 Jan;44(1):54-60
European journal of cancer (Oxford, England : 1990) 2008 Jan;44(1):54-60
The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells.
Al-Minawi AZ, Saleh-Gohari N, Helleday T
Nucleic acids research 2008 Jan;36(1):1-9
Nucleic acids research 2008 Jan;36(1):1-9
Molecular characterization of spontaneous mesenchymal stem cell transformation.
Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A
PloS one 2008 Jan 2;3(1):e1398
PloS one 2008 Jan 2;3(1):e1398
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H
Cancer science 2007 Sep;98(9):1336-43
Cancer science 2007 Sep;98(9):1336-43
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.
Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC
Annals of oncology : official journal of the European Society for Medical Oncology 2007 Jun;18(6):1043-50
Annals of oncology : official journal of the European Society for Medical Oncology 2007 Jun;18(6):1043-50
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jul 1;13(13):3855-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jul 1;13(13):3855-9
XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
Wu Y, Zacal NJ, Rainbow AJ, Zhu XD
DNA repair 2007 Feb 4;6(2):157-66
DNA repair 2007 Feb 4;6(2):157-66
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators
The New England journal of medicine 2006 Sep 7;355(10):983-91
The New England journal of medicine 2006 Sep 7;355(10):983-91
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ
Lung cancer (Amsterdam, Netherlands) 2005 Nov;50(2):211-9
Lung cancer (Amsterdam, Netherlands) 2005 Nov;50(2):211-9
Influence of oxygen on the radiosensitivity of human glioma cell lines.
Murray D, Mirzayans R, Scott AL, Allalunis-Turner MJ
American journal of clinical oncology 2003 Oct;26(5):e169-77
American journal of clinical oncology 2003 Oct;26(5):e169-77
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of ERCC1 was performed by loading 25 µg of Hela cell lysates onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked at 4ºC overnight. The membrane was probed with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1:200 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at ~39 kDa.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human lung adenocarcinoma (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human tonsil tissue (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Rat lymph node (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of ERCC1 in Hela cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of ERCC1 in HepG2 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of ERCC1 in NIH-3T3 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 0.5 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.